Publications
Detailed Information
The pNNx Heart Rate Variability Statistics: An Application to Neuroautonomic Dysfunction of Clozapine-Treated Subjects
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Jong-Hoon | - |
dc.contributor.author | Yi, Sang Hoon | - |
dc.contributor.author | Ahn, Yong Min | - |
dc.contributor.author | Lee, Kyu Young | - |
dc.contributor.author | Kim, Yong Sik | - |
dc.contributor.author | Yang, Seung Ae | - |
dc.date.accessioned | 2012-07-05T00:52:01Z | - |
dc.date.available | 2012-07-05T00:52:01Z | - |
dc.date.issued | 2009-12 | - |
dc.identifier.citation | PSYCHIATRY INVESTIGATION; Vol.6 4; 294-298 | ko_KR |
dc.identifier.issn | 1738-3684 | - |
dc.identifier.uri | https://hdl.handle.net/10371/78529 | - |
dc.description.abstract | Objective The percentage Of Successive normal cardiac interbeat intervals greater than 50 msec (pNN50) is a widely used heart rate variability measure, which is useful in identifying the neuroautonomic dysfunction of psychiatric disorders. However, pNN50 is only one member of a larger family of pNNx statistics, where x is greater than 0 msec. The potential application of the general pNNx statistics has not yet been explored in the psychiatric field. The authors examined the pNNx statistics in clozapine-treated subjects and normal controls to evaluate the usefulness of the general pNNx statistics. Methods Sixty-one schizophrenic patients treated with clozapine and fifty-nine normal controls were evaluated. probability values for the differences between the groups at each pNN value (range: pNN1-pNN100) were calculated using data obtained from a 30-minute electrocardiogram. Results The conventional pNN50 and pNNx values with x<50 msec were all significantly lower in the patient group (p<0.05). The distinction between the two groups was more prominent at pNN values less than 50 msec than that observed at pNN50. The maximum separation between groups occurred at pNN5 (68.2 +/- 19.1 vs 22.5 +/- 20.5, p<10(-22)). Conclusion The pNNx with x<50 msec provided more robust discrimination between the groups than the conventional pNN50, suggesting the importance of analyzing very small variations of interbeat interval in discriminating normal and pathological heart rate patterns. The results also Suggest that the general pNNx statistics may be applied and useful in evaluating the neuroautonomic dysfunction in patients treated with clozapine, complementing the traditionally Computed pNN50 value. Psychiatry Invest 2009;6:294-298 | ko_KR |
dc.description.sponsorship | This study was supported in part by the
Brain Korea 21 project for Medicine, Dentistry, and Pharmacy (Seoul National University) and by Grant No. 04-2006-0540 from Seoul National University Hospital. | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | KOREAN NEUROPSYCHIATRIC ASSOC | ko_KR |
dc.subject | Heart rate variability | ko_KR |
dc.subject | Neuroautonomic dysfunction | ko_KR |
dc.subject | Clozapine | ko_KR |
dc.subject | pNNx statistics | ko_KR |
dc.subject | Schizophrenia | ko_KR |
dc.title | The pNNx Heart Rate Variability Statistics: An Application to Neuroautonomic Dysfunction of Clozapine-Treated Subjects | ko_KR |
dc.type | Article | ko_KR |
dc.contributor.AlternativeAuthor | 김종훈 | - |
dc.contributor.AlternativeAuthor | 이상훈 | - |
dc.contributor.AlternativeAuthor | 안용민 | - |
dc.contributor.AlternativeAuthor | 이규영 | - |
dc.contributor.AlternativeAuthor | 양승애 | - |
dc.contributor.AlternativeAuthor | 김용식 | - |
dc.identifier.doi | 10.4306/pi.2009.6.4.294 | - |
dc.citation.journaltitle | PSYCHIATRY INVESTIGATION | - |
dc.description.citedreference | Duschek S, 2009, HYPERTENS RES, V32, P938, DOI 10.1038/hr.2009.115 | - |
dc.description.citedreference | Lollgen D, 2009, MUSCLE NERVE, V39, P536, DOI 10.1002/mus.21242 | - |
dc.description.citedreference | Siepmann M, 2008, APPL PSYCHOPHYS BIOF, V33, P195, DOI 10.1007/s10484-008-9064-z | - |
dc.description.citedreference | Bar KB, 2008, J CLIN PSYCHOPHARM, V28, P694, DOI 10.1097/JCP.0b013e31818a6d25 | - |
dc.description.citedreference | Bar KJ, 2008, PSYCHIAT RES, V157, P255, DOI 10.1016/j.psychres.2007.04.021 | - |
dc.description.citedreference | Bar KJ, 2007, CLIN NEUROPHYSIOL, V118, P2009, DOI 10.1016/j.clinph.2007.06.012 | - |
dc.description.citedreference | Bar KJ, 2007, SCHIZOPHR RES, V95, P115, DOI 10.1016/j.schres.2007.05.034 | - |
dc.description.citedreference | Kim JH, 2006, EUR NEUROPSYCHOPHARM, V16, P459, DOI 10.1016/j.euroneuro.2005.11.003 | - |
dc.description.citedreference | Mujica-Parodi LR, 2005, NEUROPSYCHOBIOLOGY, V51, P10, DOI 10.1159/000082850 | - |
dc.description.citedreference | KIM W, 2005, J KOREAN NEUROPSYCHI, V44, P176 | - |
dc.description.citedreference | Tank J, 2004, HYPERTENSION, V43, P1035, DOI 10.1161/01.HYP.0000125729.90521.94 | - |
dc.description.citedreference | Kim JH, 2004, PROG NEURO-PSYCHOPH, V28, P371, DOI 10.1016/j.pnpbp.2003.11.007 | - |
dc.description.citedreference | Mueck-Weymann M, 2004, CLIN AUTON RES, V14, P15, DOI 10.1007/s10286-004-0123-0 | - |
dc.description.citedreference | Yeragani VK, 2003, PSYCHIAT RES, V121, P185, DOI 10.1016/S0165-1781(03)00235-X | - |
dc.description.citedreference | Agelink MW, 2003, PHARMACOPSYCHIATRY, V36, P166 | - |
dc.description.citedreference | Mietus JE, 2002, HEART, V88, P378 | - |
dc.description.citedreference | Yeragani VK, 2002, BIOL PSYCHIAT, V52, P418 | - |
dc.description.citedreference | Eschweiler GW, 2002, PHARMACOPSYCHIATRY, V35, P96 | - |
dc.description.citedreference | Goldberger AL, 2002, P NATL ACAD SCI USA, V99, P2466, DOI 10.1073/pnas.012579499 | - |
dc.description.citedreference | Ansakorpi H, 2002, J NEUROL NEUROSUR PS, V72, P26 | - |
dc.description.citedreference | MALASPINA D, 2002, CNS SPECTRUMS, V7, P53 | - |
dc.description.citedreference | Mueck-Weymann M, 2002, DEPRESS ANXIETY, V16, P93, DOI 10.1002/da.10037 | - |
dc.description.citedreference | Cohen H, 2001, BRIT J PSYCHIAT, V179, P167 | - |
dc.description.citedreference | Haapaniemi TH, 2001, J NEUROL NEUROSUR PS, V70, P305 | - |
dc.description.citedreference | Cohen H, 2001, CLIN NEUROPHARMACOL, V24, P106 | - |
dc.description.citedreference | Agelink MW, 2001, J CLIN PSYCHOPHARM, V21, P8 | - |
dc.description.citedreference | Toichi M, 1999, INT J PSYCHOPHYSIOL, V31, P147 | - |
dc.description.citedreference | Malaspina D, 1997, BIOL PSYCHIAT, V41, P612 | - |
dc.description.citedreference | Korpelainen JT, 1996, STROKE, V27, P2059 | - |
dc.description.citedreference | HALL RCW, 1995, PSYCHOSOMATICS, V36, P267 | - |
dc.description.citedreference | RECHLIN T, 1994, BIOL PSYCHIAT, V35, P888 | - |
dc.description.citedreference | *AM PSYCH ASS, 1994, DIAGN STAT MAN MENT, P273 | - |
dc.description.citedreference | HUIKURI HV, 1990, AM J CARDIOL, V65, P391 | - |
dc.description.citedreference | BIGGER JT, 1988, AM J CARDIOL, V61, P208 | - |
dc.description.citedreference | KAY SR, 1987, SCHIZOPHRENIA BULL, V13, P261 | - |
dc.description.citedreference | EWING DJ, 1984, BRIT HEART J, V52, P396 | - |
dc.description.citedreference | GUY W, 1976, ECDEU ASSESSMENT PSY | - |
dc.description.tc | 2 | - |
- Appears in Collections:
- Files in This Item:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.